Lyell Immunopharma, Inc. (NASDAQ:LYEL) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Key Points

• Analysts hold a “Moderate Buy” consensus on Lyell Immunopharma, with six buy ratings, one strong buy, one hold and one sell. The average 12-month price target is $40.86.
• LYEL opened at $9.41, near its 12-month low of $9.36 and down 3.9%, while its 12-month high is $45.00.
• Institutional investors own 66.05% of the company’s shares. Lyell posted quarterly EPS of negative $1.92, slightly better than analysts’ expected loss of $1.94, but reported no revenue and significant negative profitability metrics.

Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the nine analysts that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $40.86.

A number of equities research analysts recently issued reports on the company. HC Wainwright reissued a "buy" rating on shares of Lyell Immunopharma in a research report on Friday, September 11th. Royal Bank Of Canada set a $34.00 price target on Lyell Immunopharma in a research report on Friday, August 14th. Wall Street Zen raised shares of Lyell Immunopharma from a "sell" rating to a "hold" rating in a research note on Saturday, September 26th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Lyell Immunopharma in a report on Friday, July 17th. Finally, Citigroup reissued a "market outperform" rating on shares of Lyell Immunopharma in a research report on Friday, August 14th.

Institutional Investors Weigh In On Lyell Immunopharma

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Velan Capital Investment Management LP boosted its position in Lyell Immunopharma by 2.9% during the second quarter. Velan Capital Investment Management LP now owns 105,000 shares of the company's stock valued at $1,475,000 after purchasing an additional 3,000 shares during the last quarter. BBR Partners LLC bought a new position in Lyell Immunopharma in the fourth quarter valued at approximately $210,000. Walleye Capital LLC acquired a new position in shares of Lyell Immunopharma during the 1st quarter worth approximately $445,000. Squarepoint Ops LLC raised its stake in shares of Lyell Immunopharma by 119.4% during the 2nd quarter. Squarepoint Ops LLC now owns 42,322 shares of the company's stock worth $595,000 after purchasing an additional 23,028 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in shares of Lyell Immunopharma during the 2nd quarter worth approximately $347,000. 66.05% of the stock is currently owned by institutional investors and hedge funds.

Lyell Immunopharma Trading Down 3.9%

LYEL opened at $9.41 on Friday. The stock has a market capitalization of $230.54 million, a P/E ratio of -0.73 and a beta of -0.03. Lyell Immunopharma has a 12 month low of $9.36 and a 12 month high of $45.00. The firm's fifty day simple moving average is $13.03 and its 200 day simple moving average is $15.92.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($1.92) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.94) by $0.02. Lyell Immunopharma had a negative return on equity of 91.62% and a negative net margin of 920,285.25%.The firm had revenue of $0.00 million during the quarter, compared to analysts' expectations of $0.00 million. On average, equities research analysts predict that Lyell Immunopharma will post -7.16 EPS for the current fiscal year.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc is a clinical-stage biotechnology company focused on developing T-cell therapies for patients with cancer. The company's research is aimed at addressing challenges that can limit the effectiveness of cellular immunotherapies, including T-cell exhaustion, inadequate persistence and difficulty penetrating solid tumors.

Lyell uses its cellular reprogramming and genetic engineering technologies to develop therapeutic T cells, including chimeric antigen receptor (CAR) T-cell candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.